Products

See leaflet

Signum®
decitabine

Indications

  • Adult patients with Myelodysplastic Syndromes (MDS)
  • Previously treated and untreated, de novo and secondary Myelodysplastic Syndromes of all French-AmericanBritish subtypes
  • Intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

Presentations

  • 50 mg x 1 vial